Page - 121 - in Cancer Nanotheranostics - What Have We Learnd So Far?
Image of the Page - 121 -
Text of the Page - 121 -
Clift et al. Theranosticnanoparticlesand thebloodstream
subsequent cell interaction of polymer coated
SPIONs in vitro. Nanoscale 5, 3723–3732. doi:
10.1039/c2nr33134a
Hirsch, V., Kinnear, C., Rodriquez-Lorenzo, L.,
Monnier, C. A., Rothen-Rutishauser, B., Balog,
S., et al. (2014). In vitro dosimetry of agglomer-
ates.Nanoscale 7, 7325–7331. doi: 10.1039/c4nr0
0460d
ISO. (2008). International Organization for
Standardization (ISO) Technical Specification
(ISO/TS) 27687:2008; Nanotechnologies –
Terminology and Definitions for Nano-Objects –
anoparticle, Nanofibre and Nanoplate; First
published2008-08-15.
Kempe, M., Kempe, H., Snowball, I., Wallen, R.,
Arza, C. R., Gotberg, M., et al. (2010). The
use of magnetite nanoparticles for implant-
assistedmagnetic drug targeting in thrombolytic
therapy. Biomaterials 31, 9499–9510. doi:
10.1016/j.biomaterials.2010.07.107
Kim, H., Lee, S., and Chen, X. (2013).
Nanotheranostics for personalized medicine.
Expert Rev. Mol. Diagn. 13, 257–269. doi:
10.1586/erm.13.15
Kreyling, W. G., Semmler-Behnke, M., Takenaka,
S., and Möller, W. (2012). Differences in the
biokinetics of inhaled nano- versus micrometer-
sized particles.Acc. Chem. Res. 46, 714–722. doi:
10.1021/ar300043r
Krol, S.,Macrez, R., Docagne, F., Defer, G., Laurent,
S., Rahman,M., et al. (2013). Therapeutic bene-
fits fromnanoparticles: the potential significance
ofnanoscience indiseaseswithcompromise to the
blood brain barrier.Chem. Rev. 113, 1877–1903.
doi:10.1021/cr200472g
Li, L., Wan, H., Ong, Z. Y., Xu, K., Ee, P. L. R.,
Zheng, S., et al. (2010). Polymer- and lipid-
based nanoparticle therapeutics for the treat-
mentof liverdiseases.Nanotoday 5, 296–312. doi:
10.1016/j.nantod.2010.06.007
Liu, G., Garrett, M. R., Men, P., Zhu, X., Perry,
G., and Smith, M. A. (2005). Nanoparticle and
other metal chelation therapeutics in Alzheimer
disease. Biochim. Biophys. Acta Mol. Basis Dis.
1741, 246–252. doi: 10.1016/j.bbadis.2005.
06.006
Liu, Y., Tan, J., Thomas, A., Ou-Yang, D., and
Muzykantov, V. R. (2012). The shape of things to come: importance of design in nanotechnol-
ogy fordrugdelivery.Ther.Deliv. 3, 181–194.doi:
10.4155/tde.11.156
Lynch, I., Dawson, K. A., and Linse, S. (2006).
Detecting cryptic epitopes created by
nanoparticles. Sci. STKE 2006:pe14. doi:
10.1126/stke.3272006pe14
Mamalis,A.G. (2007).Recent advances innanotech-
nology. J. Mater. Process Tech. 181, 52–58. doi:
10.1016/j.jmatprotec.2006.03.052
McMillan, J., Batrakova, E., and Gendelman,
H. E. (2014). Cell delivery of therapeutic
nanoparticles. Prog Mol. Biol. Transl. Sci. 104,
563–601. doi: 10.1016/B978-0-12-416020-0.
00014-0
Melancon, M. P., Stafford, R. J., and Lia, C.
(2012). Challenges to effective cancer nanother-
anostics. J. Control Release 164, 177–182. doi:
10.1016/j.jconrel.2012.07.045
Muthu,M. S., Leong, D. T.,Mei, L., and Feng, S.-S.
(2014). Nanotheranostics – Application and fur-
ther development of nanomedicine strategies for
advanced Theranostics. Theranostics 4, 660–677.
doi:10.7150/thno.8698
Najafi, S., Pazhouhnia, Z., Ahmadi, O., Berenjian,
A., and Jafarizadeh-Malmiri, H. (2014). Chitosan
nanoparticles andtheir applications indrugdeliv-
ery:areview.Curr.Res.DrugDiscov. 1,17–25.doi:
10.3844/crddsp.2014.17.25
Nichols, J. W., and Bae, Y. H. (2012). Odyssey
of a cancer nanoparticle: from injection site
to site of action. Nanotoday 7, 606–618. doi:
10.1016/j.nantod.2012.10.010
Nicolaides,N.C.,O’Shannessy,D. J., Albone, E., and
Grasso, L. (2014). Co-development of diagnostic
vectors to support targeted therapies and thera-
nostics: essential tools inpersonalizedcancer ther-
apy. Front. Oncol. 4:141. doi: 10.3389/fonc.2014.
00141
Niemirowicz, K., Markiewicz, K. H., Wilczewska,
A. Z., and Car, H. (2012). Magnetic nanopar-
ticles as new diagnostic tools in medicine. Adv.
Med. Sci. 57, 196–207. doi: 10.2478/v10039-012-
0031-9
Petros, R.A., andDeSimone, J.M. (2010). Strategies
in the design of nanoparticles for therapeutic
applications.Nat. Rev. Drug Discov. 9, 615–627.
doi:10.1038/nrd2591 Pison, U., Welte, T., Giersig, M., and Groneberg,
D. A. (2006). Nanomedicine for respiratory dis-
eases. Eur. J. Pharmacol. 533, 341–350. doi:
10.1016/j.ejphar.2005.12.068
Rothen-Rutishauser, B. M., Schürch, S., Haenni, B.,
Kapp, N., and Gehr, P. (2006). Interaction of
fine particles and nanoparticles with red blood
cells visualized with advanced microscopic tech-
niques. Environ. Sci. Technol. 40, 4353–4359. doi:
10.1021/es0522635
Thon, J. N., Mazutis, L., Wu, S., Sylman, J. L.,
Ehrlicher,A.,Machlus,K.R., et al. (2014).Platelet
bioreactor-on-a-chip.Blood. 124, 1857–1867. doi:
10.1182/blood-2014-05-574913
Xie, J., Lee, S., and Chen, X. (2011). Nanoparticle-
basedtheranosticagents.Adv.Drug.Deliv.Rev.62,
1064–1079.doi:10.1016/j.addr.2010.07.009
Ye, L., Yong, K.-T., Liu, L., Roy, I., Hu, R., Zhu, J.,
etal. (2012).Apilotstudyinnon-humanprimates
shows no adverse response to intravenous injec-
tionof quantumdots.Nat.Nanotech. 7, 453–458.
doi:10.1038/nnano.2012.74
Conflict of Interest Statement:The authors declare
that the researchwasconducted in theabsenceof any
commercial or financial relationships that could be
construedasapotential conflictof interest.
Received: 22October 2014; accepted: 21 January 2015;
publishedonline:10February2015.
Citation: Clift MJD, Dechézelles J-F, Rothen-
Rutishauser B and Petri-Fink A (2015) A biological
perspective toward the interaction of theranostic
nanoparticles with the bloodstream – what needs to
be considered? Front. Chem. 3:7. doi: 10.3389/fchem.
2015.00007
This article was submitted to Chemical Engineering, a
sectionof the journalFrontiers inChemistry.
Copyright © 2015 Clift, Dechézelles, Rothen-
Rutishauser and Petri-Fink. This is an open-access
article distributed under the terms of the Creative
Commons Attribution License (CCBY). The use, dis-
tribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited
andthat theoriginalpublication in this journal is cited,
in accordancewith accepted academic practice.Nouse,
distributionorreproductionispermittedwhichdoesnot
complywith these terms.
Frontiers inChemistry | ChemicalEngineering February2015 |Volume3 |Article7 | 121
Cancer Nanotheranostics
What Have We Learnd So Far?
- Title
- Cancer Nanotheranostics
- Subtitle
- What Have We Learnd So Far?
- Authors
- João Conde
- Pedro Viana Baptista
- Jesús M. De La Fuente
- Furong Tian
- Editor
- Frontiers in Chemistry
- Date
- 2016
- Language
- English
- License
- CC BY 4.0
- ISBN
- 978-2-88919-776-7
- Size
- 21.0 x 27.7 cm
- Pages
- 132
- Keywords
- Nanomedicine, Nanoparticles, nanomaterials, Cancer, heranostics, Immunotherapy, bioimaging, Drug delivery, Gene Therapy, Phototherapy
- Categories
- Naturwissenschaften Chemie